2527-03-9

Basic information

• Product Name: 2-phenyl-1,2-benzisothiazol-3-(2H)-one
• Synonyms: 2-phenyl-1,2-benzisothiazol-3-(2H)-one;2-Phenyl-1-thia-2-azaindan-3-one;2-Phenyl-2,3-dihydro-1,2-benzoisothiazole-3-one;PZ-25;RP-62373
• CAS NO: 2527-03-9
• Molecular Formula: C₁₃H₉NOS
• Molecular Weight: 227.28
• Mol File: 2527-03-9.mol
• Article Data: 47

Chemical Properties

• Melting Point: 139-140 °C(Solv: ethanol (64-17-5))
• Boiling Point: 388.9°Cat760mmHg
• Flash Point: 189°C
• Appearance: /
• Density: 1.338g/cm³
• Vapor Pressure: 2.97E-06mmHg at 25°C
• Refractive Index: 1.698
• PKA: -0.55±0.20(Predicted)
• CAS DataBase Reference: 2-phenyl-1,2-benzisothiazol-3-(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-phenyl-1,2-benzisothiazol-3-(2H)-one(2527-03-9)
• EPA Substance Registry System: 2-phenyl-1,2-benzisothiazol-3-(2H)-one(2527-03-9)

Safety Data

• Hazardous Substances Data: 2527-03-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H9NOS/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H

Upstream product

• 19602-82-5 2,2'-dithiodibenzoic acid dichloride 
• 62-53-3 aniline 
• 5054-53-5 (Z)-N-phenyl-3H-benzo[c][1,2]dithiol-3-imine 
• 3950-02-5 2-chlorosulfenylbenzoyl chloride 
• 79054-68-5 N-phenyl-2-(methylsulfinyl)benzamide 
• 109938-67-2 N-phenyl-2-(benzylthio)benzamide 
• 18205-99-7 2-mercapto-N-phenylbenzamide 
• 863194-15-4 N-phenyl-2-(2-pyridin-4-yl-ethylsulfinyl)benzamide 
• 74-88-4 methyl iodide 
• 2527-63-1 2,2'-dithiobis(N-phenylbenzamide) 
• 4892-02-8 Methyl thiosalicylate 
• 119-80-2 2,2'-dithiobenzoic acid 
• 609-67-6 2-Iodobenzoyl chloride 
• 88-67-5 2-Iodobenzoic acid 

Downstream Products

• 56424-74-9 3-hydroxy-benzo[b]thiophene-2-carboxylic acid anilide 
• 4163-04-6 3-chloro-2-phenyl-benzo[d]isothiazolium; chloride 
• 75190-29-3 2-Phenyl-3-phenylimino-1,2-benzisothiazolin 
• 109806-80-6 N-phenyl-2-(phenylthio)benzamide 
• 23343-16-0 N-phenyl-2-(methylthio)benzamide 
• 3159-07-7 dibenzo[b,f][1,4]thiazepin-11-one 

Relevant articles and documents

No-carrier-added labeling of the neuroprotective Ebselen with selenium-73 and selenium-75

Selenium-73 is a positron emitting non-standard radionuclide, which is suitable for positron emission tomography. A copper-catalyzed reaction allowed no-carrier-added labeling of the anti-inflammatory seleno-organic compound Ebselen with 73Se and 75Se under addition of sulfur carrier in a one-step reaction. The new authentically labeled radioselenium molecule is thus available for preclinical evaluation and positron emission tomography studies.

Structure-Activity Studies Reveal Scope for Optimisation of Ebselen-Type Inhibition of SARS-CoV-2 Main Protease

The reactive organoselenium compound ebselen is being investigated for treatment of coronavirus disease 2019 (COVID-19) and other diseases. We report structure-activity studies on sulfur analogues of ebselen with the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro), employing turnover and protein-observed mass spectrometry-based assays. The results reveal scope for optimisation of ebselen/ebselen derivative- mediated inhibition of Mpro, particularly with respect to improved selectivity.

High-throughput tandem-microwell assay for ammonia repositions FDA-Approved drugs to inhibit Helicobacter pylori urease

To date, little attempt has been made to develop new treatments for Helicobacter pylori (H. pylori), although the community is aware of the shortage of treatments for H. pylori. In this study, we developed a 192-tandem-microwell-based high-throughput assay for ammonia that is a known virulence factor of H. pylori and a product of urease. We could identify few drugs, that is, panobinostat, dacinostat, ebselen, captan, and disulfiram, to potently inhibit the activity of ureases from bacterial or plant species. These inhibitors suppress the activity of urease via substrate-competitive or covalent-allosteric mechanism, but all except captan prevent the antibiotic-resistant H. pylori strain from killing human gastric cells, with a more pronounced effect than acetohydroxamic acid, a well-known urease inhibitor and clinically used drug for the treatment of bacterial infection. This study offers several bases for the development of new treatments for urease-containing pathogens and to study the mechanism responsible for the regulation of urease activity.